United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

equine) 1g/10ml solution for injection vials (imported (croatia) - european viper snake venom antiserum - solution for injection - 100mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

equine) 1g/10ml solution for injection vials (imported (croatia) - european viper snake venom antiserum - solution for injection - 100mg/1ml

United States - English - NLM (National Library of Medicine)

boiron - vipera berus venom (unii: 0oro6nca4m) (vipera berus venom - unii:0oro6nca4m) - relieves painful legs improved by elevation * see symptoms on front panel. stop use and ask a doctor if symptoms persist for more than 3 days or worsen.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 1000 mg; alogliptin benzoate, quantity: 17 mg (equivalent: alogliptin, qty 12.5 mg) - tablet, film coated - excipient ingredients: mannitol; purified talc; iron oxide yellow; povidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; crospovidone; hypromellose - vipdomet is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,vipdomet can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 500 mg; alogliptin benzoate, quantity: 17 mg (equivalent: alogliptin, qty 12.5 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; mannitol; magnesium stearate; titanium dioxide; hypromellose; crospovidone; povidone; purified talc; iron oxide yellow - vipdomet is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,vipdomet can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 850 mg; alogliptin benzoate, quantity: 17 mg (equivalent: alogliptin, qty 12.5 mg) - tablet, film coated - excipient ingredients: titanium dioxide; crospovidone; povidone; microcrystalline cellulose; mannitol; purified talc; magnesium stearate; iron oxide yellow; hypromellose - vipdomet is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,vipdomet can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - alogliptin benzoate, quantity: 34 mg - tablet, film coated - excipient ingredients: iron oxide red; microcrystalline cellulose; hyprolose; macrogol 8000; croscarmellose sodium; mannitol; titanium dioxide; hypromellose; magnesium stearate; shellac; ethanol absolute; iron oxide black; 1-butanol - vipidia is indicated to improve glycaemic control in adult patients (>= 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control, as add on to metformin, a sulphonylurea, a thiazolidinedione, insulin (with or without metformin), or in combination with metformin and a thiazolidinedione when dual therapy does not provide adequate glycaemic control.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - alogliptin benzoate, quantity: 8.5 mg - tablet, film coated - excipient ingredients: mannitol; hypromellose; macrogol 8000; hyprolose; microcrystalline cellulose; titanium dioxide; croscarmellose sodium; magnesium stearate; iron oxide red; shellac; ethanol absolute; iron oxide black; 1-butanol - vipidia is indicated to improve glycaemic control in adult patients (>= 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control, as add on to metformin, a sulphonylurea, a thiazolidinedione, insulin (with or without metformin), or in combination with metformin and a thiazolidinedione when dual therapy does not provide adequate glycaemic control.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - alogliptin benzoate, quantity: 17 mg - tablet, film coated - excipient ingredients: hyprolose; hypromellose; titanium dioxide; macrogol 8000; microcrystalline cellulose; mannitol; iron oxide yellow; croscarmellose sodium; magnesium stearate; shellac; ethanol absolute; iron oxide black; 1-butanol - vipidia is indicated to improve glycaemic control in adult patients (>=18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control, as add on to metformin, a sulphonylurea, a thiazolidinedione, insulin (with or without metformin), or in combination with metformin and a thiazolidinedione when dual therapy does not provide adequate glycaemic control.

Ireland - English - HPRA (Health Products Regulatory Authority)

ltt pharma limited - macrogol 3350; potassium chloride; ascorbic acid; sodium sulfate anhydrous; sodium chloride; sodium ascorbate - powder for oral solution - osmotically acting laxatives; macrogol, combinations